NO20064788L - Anti-myostatin-anistoffer - Google Patents

Anti-myostatin-anistoffer

Info

Publication number
NO20064788L
NO20064788L NO20064788A NO20064788A NO20064788L NO 20064788 L NO20064788 L NO 20064788L NO 20064788 A NO20064788 A NO 20064788A NO 20064788 A NO20064788 A NO 20064788A NO 20064788 L NO20064788 L NO 20064788L
Authority
NO
Norway
Prior art keywords
antibodies
myostatin
epitope
anistoffer
increasing
Prior art date
Application number
NO20064788A
Other languages
English (en)
Norwegian (no)
Inventor
Kristine Kay Kikly
Rosamund Carol Smith
Linda O Tobias
Bomie Han
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35064367&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064788(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20064788L publication Critical patent/NO20064788L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
NO20064788A 2004-03-23 2006-10-23 Anti-myostatin-anistoffer NO20064788L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55545604P 2004-03-23 2004-03-23
US55962104P 2004-04-05 2004-04-05
PCT/US2005/009307 WO2005094446A2 (en) 2004-03-23 2005-03-17 Anti-myostatin antibodies

Publications (1)

Publication Number Publication Date
NO20064788L true NO20064788L (no) 2006-12-05

Family

ID=35064367

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064788A NO20064788L (no) 2004-03-23 2006-10-23 Anti-myostatin-anistoffer

Country Status (14)

Country Link
US (1) US20070178095A1 (de)
EP (1) EP1733041B1 (de)
JP (1) JP4695133B2 (de)
KR (1) KR20060133049A (de)
AT (1) ATE557042T1 (de)
AU (1) AU2005227896B2 (de)
BR (1) BRPI0508716A (de)
CA (1) CA2558805C (de)
EA (1) EA014112B1 (de)
ES (1) ES2384176T3 (de)
IL (1) IL177956A (de)
MX (1) MXPA06010929A (de)
NO (1) NO20064788L (de)
WO (1) WO2005094446A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130036378A (ko) 2002-12-20 2013-04-11 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
TW200724548A (en) * 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
BRPI0616923A2 (pt) * 2005-10-06 2011-07-05 Lilly Co Eli anticorpos monoclonais, seus usos e composição farmacêutica
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
CA2632544C (en) * 2005-12-06 2014-09-23 Amgen Inc. Use of myostatin antagonist for treating the effects of hypogonadism
IN2014DN10515A (de) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
DK2066695T3 (da) * 2006-09-05 2013-06-10 Lilly Co Eli Anti-myostatin-antistoffer
CN101678107A (zh) 2007-08-03 2010-03-24 萨米特公开有限公司 用于治疗杜兴型肌营养不良的药物组合物
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
HUP0800448A2 (en) * 2008-07-21 2011-02-28 Pecsi Tudomanyegyetem Diagnosis of systemic diseases
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
FR2943249B1 (fr) * 2009-03-18 2011-08-12 Genethon Utilisation de la decorine pour augmenter la masse musculaire
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
JP6030452B2 (ja) 2010-11-30 2016-11-24 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
US8871209B2 (en) 2011-11-14 2014-10-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A
FR2982860B1 (fr) 2011-11-18 2015-07-10 Ass Fr Contre Les Myopathies Utilisation de la fibromoduline et du lumican pour augmenter la masse musculaire
RU2663141C2 (ru) * 2012-01-20 2018-08-01 Джензим Корпорейшн Анти-cxcr3 антитела
SG11201408042YA (en) * 2012-06-15 2015-01-29 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
PT2880053T (pt) 2012-08-01 2020-05-22 Ikaika Therapeutics Llc Mitigação de fibrose e danos de tecidos por anticorpo antiltbp4
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
CA2882272C (en) 2012-08-24 2023-08-29 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc region variant
BR112015005466B1 (pt) 2012-09-13 2023-04-11 Bristol-Myers Squibb Company Polipeptídeo e seu uso, composição farmacêutica e seu uso, molécula de ácido nucleico isolada, célula hospedeira, e método de detecção ou medição da miostatina em uma amostra
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
EP4140497A1 (de) 2013-04-08 2023-03-01 President and Fellows of Harvard College Zusammensetzungen zum verjüngen von stammzellen der skelettmuskulatur
JP2016521283A (ja) 2013-05-06 2016-07-21 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 成長因子モジュレーションのための組成物および方法
EP3881859B1 (de) * 2013-06-11 2024-03-06 President and Fellows of Harvard College Zusammensetzungen zur erhöhung der neurogenese und angiogenese
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2015143123A2 (en) 2014-03-19 2015-09-24 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
AU2015342936B2 (en) 2014-11-06 2020-10-08 Scholar Rock, Inc. Anti-pro/latent-Myostatin antibodies and uses thereof
US10000560B2 (en) 2014-12-19 2018-06-19 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
MA49661A (fr) 2015-04-15 2020-06-03 Regeneron Pharma Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8
WO2017110981A1 (en) * 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3399998B1 (de) 2016-01-06 2021-07-21 President and Fellows of Harvard College Behandlung mit gdf11 zur verhinderung gewichtszunahme, zur verbesserung der glukosetoleranz und zur verringerung der hepatosteatose
WO2017120523A2 (en) 2016-01-08 2017-07-13 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
KR101822352B1 (ko) 2016-06-17 2018-01-25 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
DK3565592T5 (da) * 2017-01-06 2024-09-02 Scholar Rock Inc Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
MA52417A (fr) 2018-03-01 2021-01-06 Regeneron Pharma Procédés de modification de composition corporelle
MX2021007394A (es) 2018-12-18 2021-07-15 Regeneron Pharma Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
US20220143136A1 (en) 2018-12-21 2022-05-12 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2201076T3 (es) * 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US20030074680A1 (en) * 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
DE69633973T2 (de) * 1995-09-11 2005-12-22 Kyowa Hakko Kogyo Co., Ltd. Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
EP1075272B1 (de) * 1998-05-06 2009-07-15 Metamorphix, Inc. Verfahren zur behandlung von diabetes durch hemmung von gdf-8
US6537781B1 (en) * 1999-08-10 2003-03-25 Idexx Laboratories, Inc. Methods and compositions concerning canine interleukin 5
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof

Also Published As

Publication number Publication date
CA2558805A1 (en) 2005-10-13
MXPA06010929A (es) 2007-01-16
BRPI0508716A (pt) 2007-08-07
EP1733041A4 (de) 2009-01-28
JP4695133B2 (ja) 2011-06-08
EP1733041A2 (de) 2006-12-20
ATE557042T1 (de) 2012-05-15
ES2384176T3 (es) 2012-07-02
EA014112B1 (ru) 2010-10-29
WO2005094446A3 (en) 2005-12-22
CA2558805C (en) 2011-09-27
AU2005227896B2 (en) 2008-11-13
US20070178095A1 (en) 2007-08-02
WO2005094446A2 (en) 2005-10-13
EA200601752A1 (ru) 2007-02-27
AU2005227896A1 (en) 2005-10-13
JP2007530551A (ja) 2007-11-01
KR20060133049A (ko) 2006-12-22
IL177956A0 (en) 2006-12-31
IL177956A (en) 2010-11-30
EP1733041B1 (de) 2012-05-09

Similar Documents

Publication Publication Date Title
NO20064788L (no) Anti-myostatin-anistoffer
WO2007044411A3 (en) Anti-myostatin antibodies
UA92504C2 (en) Anti-myostatin monoclonal antibody
NL301196I2 (nl) inebilizumab
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
CY1113224T1 (el) Νεο αντισωμα αντι-ρlgf
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MX2009005743A (es) Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab.
TN2009000383A1 (en) Anti - sclerostin antibodies
EA200702053A1 (ru) Антитела против cd38 для лечения множественной миеломы
DK3284753T3 (da) Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
IL187594A0 (en) Humanized anti-cd40 antibodies and their methods of use
PH12020551037A1 (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
WO2009135861A3 (en) Humanized antibodies against human interferon-alpha
MX2022012182A (es) Metodos de uso de anticuerpos anti-trem2.
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
CR20220047A (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
WO2003073982A3 (en) Anti-interleukin-1 beta analogs
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
WO2007101021A3 (en) Humanized anti-ghrelin antibodies
ZA202205813B (en) Trpv1 epitopes and antibodies
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application